Where are we now: assessing the price, availability and affordability of essential medicines in Delhi as India plans free medicine for all by Anita Kotwani
Kotwani BMC Health Services Research 2013, 13:285
http://www.biomedcentral.com/1472-6963/13/285RESEARCH ARTICLE Open AccessWhere are we now: assessing the price, availability
and affordability of essential medicines in Delhi
as India plans free medicine for all
Anita KotwaniAbstract
Background: Inequitable access to medicines is a major weakness in the Indian health care system. Baseline data
needed to develop effective public health policy and provide equitable access to essential medicines. The present
survey was conducted to investigate the price, availability, and affordability of fifty essential medicines in the public
and private sector in Delhi, India using standardized WHO/HAI methodology.
Methods: Data on procurement price and availability was collected (July-October 2011) from three public healthcare
providers: the federal (central) government, state government and Municipal Corporation of Delhi (MCD). Data on price
and availability of medicines was collected from private retail and chain pharmacies of a leading corporate house.
Prices were compared to an international reference price (expressed as median price ratio-MPR).
Results: The procurement price of surveyed medicines was 0.53-0.82 times the international reference price-IRP.
However, the overall mean availability of surveyed medicines in facilities under state government and MCD was
41.3% and 23.2%, respectively. The overall mean availability of medicines in three tertiary care facilities operated
by the federal government was 49.3%. Availability of generic medicines was much higher in the private sector.
Off-patented medicines, like diazepam, diclofenac, and doxycycline had the highest MPRs. The price ratio
between procurement and retail was as high as 28 (range 11–28) for certain medicines. Seven-day treatment
with a popular brand of amoxicillin+clavulanic acid or one inhaler each of budesonide and salbutamol cost
2.3 and 1.4 days’ wages for the lowest paid government worker. A majority of India’s population cannot afford
these prices.
Conclusions: This study revealed that procurement prices of surveyed medicines were reasonable in comparison
to IRP. However, variation in procurement prices of certain medicines by different public procurement agencies
was noted. Availability of medicines was very poor in public sector facilities, which are the primary source of free
medicines for a majority of India’s low-income population. Availability of medicines is better in private retail
pharmacies but affordability remains a big challenge for a majority of the population. These data have significant
policy implications that could help in amending policies to increase the access to essential medicines for India’s
population.
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Access to healthcare is a fundamental human right, safe-
guarded internationally and recognized by governments
throughout the world [1,2]. In October 2010, the Planning
Commission of India constituted the High Level Expert
Group (HLEG) on Universal Health Coverage (UHC) with
the mandate of developing a framework to provide easily
accessible and affordable health care for all Indians [3].
As a first step, the federal government instituted a policy
to provide free medicines for all persons attending a
government health facility and the first phase was to
start by October 2012 [4]. This government initiative is a
step in the right direction to provide access to affordable
essential medicines [5] and is in line with fulfilling the
United Nations Millennium Development Goals [6]. Un-
fortunately, however, the federal government has already
delayed implementation of this policy.
Out-of-pocket payments account for up to 80% of
health financing in India [7]. Additionally, 70% of health
spending on outpatient treatment goes towards purchas-
ing medicines [7]. Hence, the price of essential medicines
really does matter – not only to patients, but also to
the government that has embraced the responsibility to
provide healthcare to their citizens.
This article describes the detailed reporting of pro-
curement prices and availability of a basket of essential
medicines in three major public healthcare providers and
the prices, availability and affordability of these medicines
for patients in the private sector in National Capital
Territory (NCT) of Delhi, India. This survey utilized
the standardized and validated methodology of World
Health Organization (WHO) and Health Action Inter-
national (WHO/HAI) [8,9]. Data was collected from
July-October 2011 in NCT, Delhi.
Methods
Background
Delhi, the capital of India is known as the National
Capital Territory of Delhi (NCT Delhi). NCT Delhi has
its own elected government but technically it is a federally
(centrally) administered state. The NCT Delhi is divided
into eight administrative districts.
Three main public sector health care providers in NCT
Delhi are: the Central (federal) Government under the
Ministry of Health and Family Welfare (MoH & FW), the
Directorate of Health Services (DHS) in the Government
of NCT (GNCT) Delhi and another public sector provider
in Delhi city – the Municipal Corporation of Delhi (MCD).
The central government has 3 tertiary care hospitals, 1
children’s hospital, and approximately 90 dispensaries
(primary healthcare). The Central Government dispens-
aries serve only central government employees (current
and retired). All citizens benefit from services at the
tertiary care hospitals.At the state level, the Government of NCT Delhi has
two tertiary care hospitals, 6 specialist hospitals, 15
secondary care hospitals and approximately 213 dis-
pensaries. The Municipal Corporation of Delhi (MCD)
operates 2 tertiary care hospitals, 14 polyclinic/second-
ary care hospitals and 58 dispensaries. All citizens can
visit and avail free services at all government-funded
health facilities within NCT Delhi.
Interestingly, all the three healthcare providers have
their own procurement system, essential medicine list
(EML) or procurement list of medicine and procurement
price.
Recently, chain pharmacies have entered the Indian
private retail sector. Therefore, both types of retail phar-
macies were included in the survey, the traditional pri-
vate retail pharmacies and the chain pharmacies of a
leading corporate house.
Sampling
Both public and private sector facilities were included
in the study. The survey was conducted in all the eight
districts of Delhi and five randomly selected facilities
were surveyed in each district.
Public sector
Procurement prices were collected from all the three
centralized public sector procurement agencies. The three
procurement agencies for each healthcare provider are:
Central procurement agency (CPA) for Delhi state govern-
ment; procurement department of MCD; and Medical
Stores Organization (MSO), procurement department of
central government. Three tertiary care facilities under the
central government (CG) – Lady Hardinge (LH) Medical
College and associated hospitals, Ram Manohar Lohia
(RML) Hospital, and Safdurjung Hospital (SH) also under-
take independent medicine procurements to augment the
supply received from their central agency (MSO). RML
and SH have a common pooled procurement tender
system. Therefore, procurement price data was also col-
lected from RML and from LH in addition to the three
centralized procurement agencies.
Medicines prescribed at public facilities are available
at no cost, provided they are available at the facility.
Therefore, medicine availability was collected from the
various public facilities to determine access to medicines.
For each district, one secondary care hospital and four pri-
mary care centers (dispensaries) were randomly selected.
WHO/HAI methodology requires one tertiary care to be
included in the survey; therefore, in one of the districts
one tertiary care hospital instead of secondary care was
selected. Three tertiary care level facilities under the
central government were also included. Thus, a total of
83 facilities (40 facilities under GNCT Delhi, 40 under
MCD, and 3 for CG) were surveyed.
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Private sector facilities were identified by selecting one re-
tail pharmacy outlet in each sector that was in geographic
proximity to the nearest public facility. In each district,
five retail pharmacies and five retail chain pharmacies
were included. Thus a total of 80 facilities were surveyed.
Medicines surveyed
A total of 50 medicines were surveyed. WHO/HAI meth-
odology has identified 30 core medicines – 14 essential
medicines for global burden of disease and 16 specific to
South East Asia. Apart from these core medicines a sup-
plementary list of medicines (20) were added; the names,
strength and dosage forms are detailed in Table 1. The
supplementary list included 17 commonly used antibiotics
based on their inclusion in the Delhi state EML; two in-
halers that are commonly used for asthma; and a dis-
persible zinc sulphate tablet, which is recommended by
the WHO for acute diarrhoea in children.
WHO/HAI methodology suggests that data for each
medicine should be collected for both the originator
brand, defined as the product that was first authorised
for worldwide marketing, and for the lowest-priced gen-
eric equivalent found at each facility. Until 2005, how-
ever, product patent protection was not applicable in
India and pharmaceutical companies could manufacture
medicines that were still under patent in other parts of
the world, and this allowed the Indian generic industry
to flourish. Consequently, the Indian market has generic
versions of all common medications. Nevertheless, medi-
cine manufacturers in India want to generate brand name
recognition for their product. Therefore, all products have
a brand (trade) name [10,11].
Medicines in India are known as ‘branded’ and ‘branded-
generics’. Branded medicines are manufactured by
reputable Indian manufacturers and multinational pharma-
ceutical companies. Branded medicines tend to be more
expensive than branded-generics, but are prescribed and
sold more often. Financial incentives may spur doctors to
prescribe branded medicines; but, physicians also believe
that medicines manufactured by leading companies are
more likely to be of better quality. Originators brands
(OBs) in India are also pooled with branded medicines
(popular brands) and as such do not have any additional
recognition as originator brand. Frequently OBs are not
available but the same molecules are manufactured by
other companies with different trade names that are
also recognized as ‘branded’ products. Therefore, for
this survey, in addition to collecting data for OB and
lowest-priced generic (LPG) a third category, highest-
priced generic (HPG) data was collected for a list of 30
core medicines at each private sector facility. For sup-
plementary medicines (20), highest-priced and lowest-
priced generics were surveyed at each private facility.Public sector facilities only have one version of each
medicine, the lowest-priced generic (LPG). Therefore,
data for price and availability were collected for LPG
from public sector facilities.
Data collection entry and analysis
Trained data collectors visited enrolled facilities and
recorded medicine availability and prices using a stan-
dardized form. Several validation and data checking
steps during and after data collection ensured data
quality. Data were double entered in Microsoft Excel
Workbook and the auto checker was used to assist in
the verification process [8].
The price collected from private sector is the price
charged directly to patients by each facility. For public
sector facilities, procurement prices were collected from
three central agencies - CPA for Delhi state government;
procurement department of MCD; and Medical Stores
Organization (MSO), procurement department of CG.
Procurement prices were also collected from two de-
centralized sites of CG - RML Hospital (RML/SH) and
LH Medical College and associated hospitals. Medicine
availability was also assessed at all public facilities.
Each sector’s data were analysed separately. Medicine
availability is reported as the percent availability of an indi-
vidual medicine at the surveyed outlets on the day of sur-
vey. Mean (average) percent availability across the basket of
medicines surveyed is also reported. To facilitate inter-
national comparisons, medicine prices are expressed as me-
dian price ratio (MPR) [12]. The MPR is the local median
unit price of a medicine in comparison with the median
unit price found in the Management Sciences for Health
(MSH) Price Indicator Guide, 2010 (MSH 2010), i.e. the
international reference price [13]. MSH international refer-
ence prices represent actual procurement prices for medi-
cines offered to low-income and middle-income countries
by non-profit suppliers and international tender prices.
MPR of 1 or less is taken as efficient procurement in the
public sector, while below 2.5 is considered efficient for
the private sector [14]; availability less than 30% is consid-
ered very low and greater than 80% is considered high
[14]. Data was analyzed using Microsoft Excel.
The WHO/HAI methodology also measures the af-
fordability, which is defined as the number of days an
unskilled government worker must work to purchase a
standard treatment regimen for common clinical condi-
tions. Treatment affordability is calculated using the cost
of a one month treatment for chronic diseases or the
cost of the course of therapy for acute diseases.
Ethical approval
Ethical approval of the study was obtained fromVallabhbhai
Patel Chest Institute, University of Delhi, India. Permission
for data collection was obtained from Health Department,
Table 1 List of medicines surveyed
A. List of global and WHO-SEARO regional list (30)
Amitriptyline 25 mg cap/tab Global
Amlodipine 5 mg cap/tab Regional
Amoxicillin 500 mg cap/tab Global
Amoxicillin suspension 25 mg/ml milliliter Regional
Atenolol 50 mg cap/tab Global
Atorvastatin 10 mg cap/tab Regional
Beclomethasone inhaler 200 mcg/dose dose Regional
Captopril 25 mg cap/tab Global
Ceftriaxone injection 1 g/vial vial Global






8+40 mg/ml milliliter Global
Diazepam 5 mg cap/tab Global
Diclofenac 50 mg cap/tab Global
Diethylcarbamazine citrate 50 mg cap/tab Regional
Doxycycline 100 mg cap/tab Regional
Enalapril 5 mg cap/tab Regional
Fluoxetine 20 mg cap/tab Regional
Gentamicin eye drops 0.30% milliliter Regional
Glibenclamide 5 mg cap/tab Global
Gliclazide 80 mg cap/tab Regional
Ibuprofen 400 mg cap/tab Regional
Metformin 500 mg cap/tab Regional
Metronidazole 400 mg cap/tab Regional
Omeprazole 20 mg cap/tab Global
Paracetamol suspension 24 mg/ml milliliter Global
Phenytoin 100 mg cap/tab Regional
Ranitidine 150 mg cap/tab Regional
Salbutamol inhaler 100 mcg/dose dose Global
Simvastatin 20 mg cap/tab Global










Ampicillin Suspension 125 mg/5 ml milliliter Supplementary
Azithromycin 500 mg Tab/cap Supplementary
Benzathine Penicillin
Powder
2.4 MU/vial inj Supplementary






Cefixime 200 mg Tab/cap Supplementary
Table 1 List of medicines surveyed (Continued)
Cefuroxime axetil 250 mg Tab/cap Supplementary
Cefuroxime Suspension 125 mg/5 ml milliliter Supplementary
Cephalexin 500 mg Tab/cap Supplementary
Cephalexin Syrup 250 mg/5 ml milliliter Supplementary
Erythromycin powder for
suspension
125 mg/5 ml milliliter Supplementary
Erythromycin stearate 250 mg Tab/cap Supplementary
Gentamicin injection 40 mg/ml inj Supplementary
Norfloxacin 400 mg Tab/cap Supplementary
Ofloxacin 200 mg Tab/cap Supplementary
Roxithromycin 50 mg Tab/cap Supplementary
Zinc sulphate dispersible 20 mg Tab/cap Supplementary
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Procurement price data collected for surveyed medicines
from three centralized procurement agencies and two de-
centralized sites are shown in Table 2. Number of medi-
cines being procured out of 50 surveyed medicines, median
MPR with inter-quartile ranges for the procured medicines,
and minimum and maximum MPR of medicines for each
procurement agency are mentioned in the Table 2.
A few medicines, like atenolol, ceftriaxone injection,
diazepam, diclofenac, enalapril, erythromycin stearate,
fluoxetine, metformin, and phenytoin were found to have
substantial variation in procurement price by different
agencies. Most often the tertiary care facility carrying out
independent procurement had the highest procurement
price for these medicines.
Availability of surveyed medicines
The overall mean availability of surveyed medicines in
all surveyed facilities under GNCT, Delhi, and MCD was
41.3% and 23.2% (Figure 1). The availability of surveyed
medicines in three tertiary care hospitals under CG and
one tertiary care hospital each under GNCT, Delhi and
MCDwas 60.0%, 40.0%, 42.0%, 60.0% and 28.0% (Figure 1).
Government of NCT, Delhi maintains an EML which is
used for procurement of medicines at facilities under its
purview. Out of 50 medicines surveyed, 40 medicines were
on the Delhi state EML at the time of survey. Mean avail-
ability for these 40 medicines was 48.8% in Delhi state oper-
ated facilities. Other branches in the public sector, MCD
and hospitals under Central Government do not have their
own EML but a procurement list is prepared by their re-
spective departments. MCD had a procurement price for
Table 2 Summary of median price ratios (MPRs) in various public sectors in Delhi
Procurement agency (number of
medicines purchased out of 50 medicines)
CPA (n =37) MCD (n =31) MSO (n =12) LH (n =32) RML/SH (n =27)
Median MPR 0.61 0.59 0.53 0.82 0.69
25%ile MPR 0.42 0.37 0.30 0.61 0.48
75%ile MPR 0.76 0.76 0.64 1.10 0.87
Minimum MPR 0.07 (Amlodipine) 0.07 (Amlodipine) 0.10 (Amlodipine) 0.34 (Ranitidine) 0.08 (Amlodipine)










CPA – procurement agency for Delhi state government, MCD – Municipal Corporation of Delhi, MSO – Procurement agency for Central government, LH – a
tertiary care facility of central government procurement, RML – tertiary care facility under central government that does procurement for two hospitals.
Note: MPR of Amlodipine was 0.42 for LH; MPR of Erythromycin tab was 0.61 for CPA, 0.96 for MCD, and 1.21 for LH; MPR of Fluoxetine was 0.50 for CPA and was
not procured by MCD, MSO, RML/SH.
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The mean availability of these 33 medicines was 34.0%.
Five medicines were not available at any of the facilities
surveyed under Delhi state government. In other words,
these five medicines had 0% availability: beclomethasone
inhaler, budesonide+formoterol inhaler, captopril, glicla-
zide, and dispersible zinc tablet. All five medicines were
not on the EML of Delhi state government. On the other
hand, MCD had 15 medicines with 0% availability at the
surveyed facilities.
Nine medicines were available in the range of 81-100%
at facilities under Delhi state government (Tables 3, 4
and 5) and these were: amlodipine, amoxicillin 250 mg,
atenolol, ibuprofen, norfloxacin, omeprazole, paraceta-
mol suspension, ranitidine and salbutamol inhaler. In
MCD facilities only three medicines were in this range:
amlodipine, atenolol, and omeprazole.
Availability of surveyed medicines for chronic and
acute diseases
Table 3 and Table 4 show medicine data categorized by
use in chronic and acute diseases. Availability of medicines
for treatment of depression, hyperlipidemia, and obstruct-
ive airways diseases was very poor in all facilities. Avail-
ability of medicines for acute conditions was not optimumFigure 1 Percent mean availability of surveyed medicines in various pin the public sector either. In general, availability of medi-
cines was poorer in MCD facilities compared to Delhi
state government facilities.
Availability of surveyed paediatric medicines
Paracetamol suspension, a core medicine, was available
at almost all public outlets but the availability was 75%
at MCD facilities (Table 5). Overall availability of two
antibacterial core medicines, amoxicillin suspension and
co-trimoxazole suspension was poor in the public sector.
Zinc sulphate dispersible tablets were not available in
any of the facilities.
Private sector
Price-to-patient
The median MPR for all versions, inter-percentile range,
minimum and maximum MPR found at retail pharma-
cies and retail chain pharmacies are shown in Table 6.
Findings were similar at both retail pharmacies and retail
chain pharmacies.
Price variations in public and private sector
Median MPR of lowest-priced generic (LPG) in the pri-
vate sector for diazepam, amlodipine, atenolol, enalapril,
diclofenac, and glibenclamide was 28, 23, 22, 16, 14ublic sectors.
Table 3 Availability of surveyed medicines for chronic diseases in various public sector facilities in NCT, Delhi, India
Medicines GNCT Delhi (n=40) MCD (n=40) CG (LH) CG (RML) CG (SJH) GNCTD (LNH) MCD (HRH)
(Depression Psychoanaleptics)
Amitriptyline 10.0% 0.0% Available N.A N.A N.A N.A
Fluoxetine 2.5% 0.0% Available N.A Available N.A N.A
Hypertension
Amlodipine 92.5% 90.0% Available N.A Available Available Available
Atenolol 85.0% 90.0% Available Available Available Available Available
Enalapril 42.5% 47.5% Available Available N.A Available N.A
Diabetes
Glibenclamide 77.5% 42.5% Available N.A N.A N.A N.A
Gliclazide 0.0% 35.0% N.A N.A N.A N.A N.A
Metformin 60.0% 70.0% Available Available Available Available Available
Acid related disorder
Ranitidine 85.0% 17.5% Available Available Available Available N.A
Omeprazole 85.0% 85.0% Available N.A Available Available Available
Epilepsy
Phenytoin 60.0% 15.0% Available Available Available Available Available
Hyperlipidemia
Atorvastatin 27.5% 2.5% Available N.A N.A Available Available
Simvastatin 2.5% 0.0% N.A N.A N.A N.A N.A
Obstructive airways diseases
Beclomethasone inhaler 0.0% 0.0% N.A N.A N.A N.A N.A
Budesonide inhaler 22.5% 5.0% Available N.A N.A Available N.A
Budesonide+Formoterol inhaler 0.0% 0.0% N.A N.A N.A N.A N.A
Salbutamol inhaler 85.0% 0.0% N.A N.A N.A Available N.A
GNCT Delhi: Government of NCT Delhi; MCD: Municipal Corporation of Delhi; CH: Central government; LH: Lady Hardinge Medical College and Hospital;
RML: Ram Manohar Lohia Hospital; SJH: Safdarjung Hospital; LNH: Lok Nayak Hospital; HRH: Hindu Rao Hospital.
Percent availability depicts availability of medicines in all the facilities surveyed for Government of NCT Delhi and for Municipal Corporation of Delhi. Available
and Not available (N.A) is used for availability of the medicine for only one tertiary care facility.
Availability depicted as 0.0% indicates the medicine was not available in any of the 40 facilities surveyed.
Availability depicted as N.A indicates that the particular medicine is not available in the mentioned tertiary care facility on the day of the survey.
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cefuroxime suspension and cephalexin syrup were seven
times more costly than the MPR of these medicines in
the public sector. On the other hand, budesonide inhaler,
co-trimoxazole suspension, erythromycin, gentamicin in-
jection, and salbutamol inhaler did not show much price
variation from one sector to another.
Price variation between brand, highest-priced generic
and lowest-priced generic
For certain medicines tremendous price variation was ob-
served for brand, highest-priced and lowest-priced generic
available at the surveyed facilities (Figures 2 and 3).
Overall availability
The percent availability of surveyed medicines in three
different categories at private retail pharmacies and
chain pharmacies is shown in Table 7. Originator brandwas surveyed and identified for 30 core medicines. If
only one version of the medicine (besides the originator
brand) was available then it was considered to be the
lowest-priced generic available.
Medicines with poor availability
A few medicines, such as benzathine penicillin powder, cap-
topril, diethylcarbamazepine, erythromycin powder for sus-
pension, and zinc dispersible tablet had poor overall
availability.
Medicines with only one version available
A few medicines were generally available with only one
trade name which was usually the most popular brand
name. These medicines were: beclomethasone, budesonide,
budesonide+formoterol and salbutamol inhalers, ceftriaxone
injection, cefuroxime suspension, cephalexin, cephalexin
suspension, clotrimazole cream, co-trimoxazole suspension,
Table 4 Availability of surveyed medicines for acute diseases in various public sector facilities in NCT, Delhi, India
Medicines GNCT Delhi (n=40) MCD (n=40) CG (LH) CG (RML) CG (SJH) GNCTD (LNH) MCD (HRH)
Antibacterial
Amoxicillin+Clavulanic acid 27.5% 52.5% Available N.A Available Available Available
Amoxicillin 500 70.0% 20.0% Available N.A N.A Available Available
Azithromycin 2.5% 2.5% Available N.A N.A N.A N.A
Benzathine Penicillin Powder 2.5% 0.0% N.A Available Available Available N.A
Cefixime 20.0% 27.5% N.A N.A N.A N.A Available
Ceftriaxone injection 12.5% 0.0% Available Available Available Available N.A
Cefuroxime axetil 50.0% 47.5% N.A N.A N.A Available N.A
Cephalexin 47.5% 20.0% N.A Available N.A N.A N.A
Ciprofloxacin 50.0% 72.5% Available Available Available Available Available
Doxycycline 52.5% 70.0% Available N.A N.A N.A Available
Erythromycin Stearate 47.5% 0.0% Available Available Available Available N.A
Gentamicin injection 10.0% 0.0% Available Available Available Available N.A
Norfloxacin 82.5% 2.5% Available Available Available N.A N.A
Ofloxacin 45.0% 47.5% Available Available N.A Available Available
Roxithromycin 47.5% 7.5% N.A N.A N.A Available N.A
Antifungal for topical use
Clotrimazole topical cream 62.5% 2.5% N.A N.A Available Available N.A
Psycholeptic
Diazepam 10.0% 5.0% Available Available Available N.A N.A
Antifilarial
Diethylcarbamazine citrate 2.5% 0.0% N.A N.A N.A N.A N.A
Anti-inflammatory/antirheumatic
Diclofenac 35.0% 7.5% Available Available N.A Available N.A
Ibuprofen 92.5% 15.0% Available Available Available Available N.A
Antibiotic for ophthalmic use
Gentamicin eye drops 62.5% 12.5% Available N.A Available Available N.A
Amoebia and other protozoal infections
Metronidazole 57.5% 32.5% Available N.A Available N.A N.A
GNCT Delhi: Government of NCT Delhi; MCD: Municipal Corporation of Delhi; CH: Central government; LH: Lady Hardinge Medical College and Hospital; RML: Ram
Manohar Lohia Hospital; SJH: Safdarjung Hospital; LNH: Lok Nayak Hospital; HRH: Hindu Rao Hospital.
Percent availability depicts availability of medicines in all the facilities surveyed for Government of NCT Delhi and for Municipal Corporation of Delhi. Available
and Not available (N.A) is used for availability of the medicine for only one tertiary care facility.
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metronidazole, norfloxacin, and roxithromycin.
Affordability
Affordability was calculated on the basis of the daily
wage of an unskilled government worker. The salary of
the lowest paid regular government worker was Indian
Rupees (INR) 247 or USD $5.5 (2011) per day. The
prices of treatments in the private retail shop and chain
pharmacies were almost equal. The cost of treatment
and affordability of four conditions is shown in Figure 4.
Calculations of affordability included only the medi-
cine price - physician consultation fees and diagnostictests will likely mean that the total cost to the patient
may be considerably higher.
Discussion
The present study is perhaps the only study that com-
pares the procurement prices and availability of a basket
of essential medicine for three public health care pro-
viders in a single state of any country. The study also
surveyed the medicine price and availability in the pri-
vate sector, from the traditional retail pharmacy shops
and recently introduced chain pharmacies.
Delhi spans a relatively small geographical area as
compared to other Indian states. Therefore, a more
Table 5 Availability of surveyed paediatric medicines in various public sector facilities in NCT, Delhi, India
Medicines GNCT, Delhi (n=40) MCD (n=40) CG (LH) CG (RML) CG (SJH) GNCTD (LNH) MCD (HRH)
Amoxicillin suspension 70.0% 5.0% Available N.A N.A Available N.A
Amoxicillin 250 82.5% 32.5% Available Available Available Available N.A
Amoxicillin+Clavulanic acid Syrup 30.0% 60.0% N.A N.A N.A Available Available
Ampicillin Suspension 22.5% 2.5% N.A N.A N.A Available N.A
Cefuroxime Suspension 5.0% 0.0% N.A N.A N.A N.A N.A
Cephalexin Syrup 47.5% 7.5% Available N.A N.A Available N.A
Co-trimoxazole suspension 35.0% 30.0% Available Available N.A N.A N.A
Paracetamol suspension 97.5% 75.0% Available Available Available Available Available
Zinc sulphate dispersible 0.0% 0.0% N.A N.A N.A N.A N.A
GNCT Delhi: Government of NCT Delhi; MCD: Municipal Corporation of Delhi; CH: Central government; LH: Lady Hardinge Medical College and Hospital; RML: Ram
Manohar Lohia Hospital; SJH: Safdarjung Hospital; LNH: Lok Nayak Hospital; HRH: Hindu Rao Hospital.
Percent availability depicts availability of medicines in all the facilities surveyed for Government of NCT Delhi and for Municipal Corporation of Delhi. Available
and Not available (N.A) is used for availability of the medicine for only one tertiary care facility.
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and private facilities was possible. Since Delhi is the
capital of the country, meetings and rapid dissemination
of results to regulatory agencies and policy makers is
possible and indeed a meeting was conducted for the
stakeholders. This article should be useful to government
health policymakers in providing a broad picture of the
present situation regarding essential medicines and
suggesting ways to strengthen the EMLs, procurement
and supply chain that will bring benefit to patients.
Despite the strengths, the WHO/HAI methodology
has few limitations. First, availability and price are deter-
mined for a specific list of survey medicines, and do not
account for alternate dosage forms of these medicines or
therapeutic alternates. Second, differences in quality
across products are not accounted for. Availability data
only refer to the day of data collection at each facility
and might not indicate average availability of medicines
over time. However, since the survey is done in several
facilities over a period of time (2–3 months), the data
provide a reasonable estimate of the overall situation
and are indicative of the real-life situation faced by the
patients on a daily basis.Table 6 Summary of medicine prices in the private sector
Private pharmacies
Brand (n =16) Highest priced (n =28) Lowest priced (n
Median MPR 4.71 5.38 2.83
25%ile MPR 2.59 2.76 1.74
75%ile MPR 7.42 6.84 5.20
Minimum MPR 0.57 0.57 0.56
Maximum MPR 16.51 9.30 9.73
Note: Minimum MPR was for ranitidine for all three versions. Maximum MPR for bra
the lowest-priced generic was for diazepam. The results were same for chain pharmPublic sector
Procurement price
All the three central procurement agencies, CPA of Delhi
state government, procurement department of MCD, and
MSO of central government have two-bid tender system.
Technically qualified companies are eligible to place a
price-bid and the rate is fixed with the company that
has the lowest quoted price. The median MPR of pur-
chased medicine by all the three agencies was less than
one, indicating the procurement price was reasonable as
compared to international reference price. Six previous
surveys conducted simultaneously in 2004 in five states
of India using WHO/HAI methodology showed median
MPR in the range of 0.27 – 0.48 for core medicines
[15]. The median MPR for core medicines procured by
the CPA, Delhi state government was found to be 0.48
in this study.
The central government procurement agency, MSO was
procuring only 12 medicines out of 50 surveyed medicines
therefore all the three tertiary care facilities under central
government make their own parallel procurement. The
median MPR for these two decentralized procurement
was 0.69 and 0.82 whereas for three central procurementChain pharmacies






nd medicine was diclofenac, for highest-priced was for doxycycline, and for
acies.
Price variation between brand and highest price and lowest priced generics 
Median price in INR
Figure 2 Price variation for a few medicines in brand, highest and lowest-priced generics available at private sector.
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http://www.biomedcentral.com/1472-6963/13/285agencies was between 0.53 - 0.61. We found variation
in procurement price for the same medicine procured by
different agencies. Generally, the procurement price of ter-
tiary care facilities conducting independent (decentralized)
procurement was much higher than other agencies. These
findings confirm that pooled procurement decreases the
procurement price [15,16]. It is established that pooled
procurement decreases the medicines’ procurement prices
and local purchase of medicines done by individual facility
cost higher [17].
Policy options for improving procurement process
The procurement agencies in a state or country should
keep each other advised on their system and the rate list
or procurement prices fixed by the respective agencies.
A common list of trustworthy companies who supplied
the medicines at required intervals could be circulated
to each other. Efforts should be made by the centralFigure 3 Price variation for selected medicines for brand, highest and
Indian Rupees.procurement agency of Central Government (MSO) to
be more efficient and to procure adequate numbers of
medicines for its facilities. The three facilities under
central government can prepare a common EML based
on essential medicine concept, combine their require-
ment of medicines, and opt for pooled procurement.
Government of NCT Delhi and MCD can have a common
list of essential medicines for primary, secondary and
tertiary care facilities which can decrease the replication of
work. To implement these policies, transparency and
accountability within the health department are a pre-
requisite [18].
Poor availability of surveyed medicines in the public sector
As mentioned earlier WHO and HAI has set a benchmark
of 80% for medicine availability as good [14,19] against
which we found that medicines for acute, chronic, and
for children were suboptimal. Availability of essentiallowest-priced generics available at private sector. Note: INR =
















Amitriptyline 25 mg cap/tab Global 65.0% 80.0% 2.5% 0.0% 12.5% 12.5%
Amlodipine 5 mg cap/tab Regional 52.5% 60.0% 82.5% 90.0% 95.0% 100.0%
Amoxicillin+clavulanic acid
500 mg+125 mg cap/tab
Supplementary NS** NS 95.0% 100.0% 100.0% 100.0%
Amoxicillin 500 mg cap/tab Global 0.0% 0.0% 95.0% 92.5% 97.5% 100.0%
Amoxicillin 250 mf cap/tab Supplementary NS NS 72.5% 97.5% 92.5% 100.0%
Amoxicillin suspension 25 mg/ml Regional 0.0% 0.0% 57.5% 70.0% 95.0% 92.5%
Amoxicillin+clavulanic acid Syrup
200 mg+28.5 mg/5 ml
Supplementary NS NS 62.5% 90.0% 92.5% 92.5%
Ampicillin Suspension 125 mg/5 ml Supplementary NS NS 2.5% 0.0% 2.5% 0.0%
Atenolol 50 mg cap/tab Global 45.0% 45.0% 67.5% 92.5% 97.5% 100.0%
Atorvastatin 10 mg cap/tab Regional 12.5% 30.0% 87.5% 85.0% 97.5% 95.0%
Azithromycin 500 mg cap/tab Supplementary NS NS 95.0% 97.5% 100.0% 100.0%
Beclomethasone inhaler 250 mcg/dose Regional 5.0% 0.0% 0.0% 0.0% 35.0% 37.5%
Benzathine Penicillin Powder 2.4 MU/vial Supplementary NS NS 0.0% 0.0% 0.0% 0.0%
Budesonide inhaler 100 mcg/dose Supplementary NS NS 7.5% 10.0% 62.5% 82.5%
Budesonide+Formoterol inhaler
100 mcg+6mcg/dose
Supplementary NS NS 0.0% 0.0% 42.5% 27.5%
Captopril 25 mg cap/tab Global 0.0% 0.0% 0.0% 0.0% 10.0% 10.0%
Cefixime 200 mg cap/tab Supplementary NS NS 80.0% 95.0% 97.5% 100.0%
Ceftriaxone injection 1 g/vial Global 0.0% 0.0% 2.5% 5.0% 47.5% 42.5%
Cefuroxime axetil 250 mg cap/tab Supplementary NS NS 55.0% 60.0% 90.0% 100.0%
Cefuroxime Suspension 125 mg/5 ml Supplementary NS NS 2.5% 0.0% 55.0% 50.0%
Cephalexin 500 mg cap/tab Supplementary NS NS 32.5% 30.0% 65.0% 80.0%
Cephalexin Syrup 250 mg/5 ml Supplementary NS NS 22.5% 22.5% 50.0% 40.0%
Ciprofloxacin 500 mg cap/tab Global 0.0% 0.0% 85.0% 92.5% 100.0% 100.0%
Clotrimazole topical cream 1% Regional 50.0% 55.0% 10.0% 17.5% 50.0% 67.5%
Co-trimoxazole suspension 8+40 mg/ml Global 5.0% 10.0% 0.0% 0.0% 77.5% 67.5%
Diazepam 5 mg cap/tab Global 35.0% 52.5% 5.0% 2.5% 37.5% 57.5%
Diclofenac 50 mg cap/tab Global 97.5% 97.5% 10.0% 12.5% 65.0% 82.5%
Diethylcarbamazine citrate 50 mg cap/tab Regional 12.5% 10.0% 0.0% 0.0% 10.0% 10.0%
Doxycycline 100 mg cap/tab Regional 0.0% 0.0% 55.0% 60.0% 97.5% 95.0%
Enalapril 5 mg cap/tab Regional 0.0% 0.0% 42.5% 32.5% 92.5% 97.5%
Erythromycin powder for suspension 125 mg/5 ml Supplementary NS NS 15.0% 15.0% 55.0% 55.0%
Erythromycin Stearate 250 mg cap/tab Supplementary NS NS 35.0% 25.0% 82.5% 85.0%
Fluoxetine 20 mg cap/tab Regional 0.0% 0.0% 42.5% 62.5% 80.0% 92.5%
Gentamicin eye drops 0.3% Regional 5.0% 2.5% 2.5% 0.0% 65.0% 50.0%
Gentamicin injection 40 mg/ml Supplementary NS NS 15.0% 17.5% 57.5% 50.0%
Glibenclamide 5 mg cap/tab Global 65.0% 72.5% 0.0% 0.0% 5.0% 7.5%
Gliclazide 80 mg cap/tab Regional 0.0% 2.5% 55.0% 67.5% 95.0% 97.5%
Ibuprofen 400 mg cap/tab Regional 95.0% 82.5% 0.0% 0.0% 45.0% 40.0%
Metformin 500 mg cap/tab Regional 0.0% 0.0% 82.5% 80.0% 97.5% 95.0%
Metronidazole 400 mg cap/tab Regional 45.0% 52.5% 2.5% 5.0% 92.5% 95.0%
Norfloxacin 400 mg cap/tab Supplementary NS NS 5.0% 0.0% 95.0% 97.5%
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Table 7 Availability of medicine surveyed in different versions in private sector (Continued)
Ofloxacin 200 mg cap/tab Supplementary NS NS 92.5% 97.5% 97.5% 100.0%
Omeprazole 20 mg cap/tab Global 0.0% 0.0% 87.5% 95.0% 100.0% 100.0%
Paracetamol suspension 24 mg/ml Global 62.5% 65.0% 20.0% 17.5% 90.0% 97.5%
Phenytoin 100 mg cap/tab Regional 37.5% 45.0% 32.5% 40.0% 90.0% 95.0%
Ranitidine 150 mg cap/tab Regional 95.0% 85.0% 82.5% 87.5% 97.5% 95.0%
Roxithromycin 50 mg cap/tab Supplementary NS NS 17.5% 25.0% 92.5% 97.5%
Salbutamol inhaler 100 mcg/dose Global 52.5% 45.0% 7.5% 7.5% 92.5% 95.0%
Simvastatin 20 mg cap/tab Global 42.5% 42.5% 2.5% 0.0% 40.0% 35.0%
Zinc sulphate dispersible 20 mg cap/tab Supplementary NS NS 0.0% 0.0% 0.0% 2.5%
*Retail indicates the retail pharmacies shops and #Chain indicates retail chain pharmacies.
OB – Originator Brand.
HPG – Highest priced generic.
LPG – Lowest priced generic.
**NS – Not surveyed.
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middle-income countries [20-22]. Availability of two
medicines for hypertension, amlodipine and atenolol
was good (>80%) in all the public sectors. Availability
of medicines for other chronic diseases, like asthma,
psychiatric conditions, and hyperlipidemia was very poor.
Earlier surveys conducted in other states of India have also
shown poor availability of essential medicines in the public
sector [15,17]. Budesonide and salbutamol inhalers were
on the Delhi state EML but they were not in the procure-
ment list of other two agencies. It is reported earlier that
inhalers were not on the procurement list of other Indian
states like Haryana, Karnataka, Maharashtra, Tamil Nadu,
and West Bengal [23]. Antidepressants agents studied,
amitriptyline and fluoxetine were on the Delhi state EML
and are also on the National EML 2011 [24] but not on
the procurement list of MCD. However, the availability of
psychiatric medicines was very poor for Delhi state and





















Figure 4 Treatment affordability for depression, hypertension, acute
outlets. Note: No. of days’ wages of lowest-paid government worker whofrom other low-and middle-income countries have shown
poor availability of medicines for chronic diseases [26-29].
Dispersible zinc tablet was not procured by any agency
though WHO recommends this medicine for treatment
of acute diarrhoea in children [30]. The second and
third generation antibiotics like cefuroxime, ofloxacin,
cefixime, amoxicillin+clavulanic acid were available at
primary healthcare facilities.
Policy options to improve availability of medicines in the
public sector
Low availability of medicines in the public sector could
results from factors such as under-budgeting, purchasing
medicines not included in the EML, inability to forecast
needs accurately, and inefficient purchasing/distribution
in the supply chain [18,20]. Various recommendations
that can improve availability of essential medicines in
the surveyed state are - Government to increase the








respiratory infection and asthma treatment in private medicine
earns Indian Rupees 247 (USD $5.5) per day.
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medicine concept; separate EML for primary care and
hospitals; procurement and distribution of medicines on
the basis of EML; efficient transparent and accountable
procurement and distribution system; prescriptions
according to STGs and EML and; regular monitoring
and evaluation of the system [31,32].
Private sector
Availability of medicines was good in the private sector
because of domestic competitive pharmaceutical indus-
try. Findings revealed that availability and price of medi-
cines were similar at traditional retail pharmacies and
chain pharmacies.
Availability price and affordability
Availability of medicines in the private sector was con-
sistently higher, though the higher prices of medicines
could hinder the access. Availability of few medicines
was found to be suboptimal; for many medicines, only
one version of the product was available that was the
costly or branded medicine (popular trade name). There-
fore, the patient has no choice but to buy that particular
costly branded product. Pharmacists will stock those
medicines that are most frequently prescribed. This indi-
cates that doctors tend to prescribe branded medicines.
Legally pharmacists are not allowed to substitute be-
tween branded and generic medicines. The brand name
(trade name) written by a doctor can not be substituted
with another. Highest MPRs were found for off-patented
medicines, like diazepam, diclofenac and doxycycline
which indicates that these medicines are very costly
compared to international reference price.
Huge price differences was observed between procure-
ment price and private retail price for certain medicines
like diazepam, amlodipine, atenolol, enalapril, diclofenac,
glibenclamide, which were 11–28 times more expensive
in the retail market than the median public procurement
price. Interestingly and unfortunately all these medicines
are used for various chronic diseases. A similar finding
for diazepam and diclofenac was observed earlier in
2003 and 2004 surveys conducted at six different states
of India [15,17]. These findings give a clue that in the
supply chain from manufacturer to retailer, one actor or
all have huge mark-ups. An earlier study on medicine
price components [10] and recent survey on tracking
medicine prices in the supply chain in Delhi [33] re-
vealed that the main profit is for the actor who is push-
ing and responsible for promoting the sale of medicine,
i.e., pharmaceutical company for branded products and
retailer for the branded-generics.
In India a few essential medicines are under price con-
trol, for most of the medicines government does not fix
the price. It is believed that free market forces will keepthe prices of medicine in-check. Findings from the pri-
vate sector indicate that the free market competition
does not seem to be driving medicine prices as low as
possible. Brand loyalty, marketing strategies do not allow
‘real’ competition in free pharmaceutical market [33]. As
the free market competition is not working to lower
medicine prices, the free market rules need to be modi-
fied by the Department of Pharmaceuticals [34] or gov-
ernment must intervene and regulate the prices of
essential medicines or provide subsidy for certain formu-
lations that are expensive.
With the lowest daily wage of government worker In-
dian Rupees 247 (USD $5.5 2011) per day, treatments
were not so affordable, e.g., adult respiratory pneumonia
if treated with amoxicillin will cost 0.8 days salary and if
treated with amoxicillin+clavulanic acid will cost 2.3
days of salary with highest-priced generic. Purchasing
one inhaler each of budesonide and salbutamol costs 1.4
days’ wages for the lowest paid government worker.
However, a large proportion of India’s population earns
less than this. According to World Bank Report, the
Gross National Income per capita for the year 2011 in
India is $1420/annum or USD $3.89 per day [35]. It is
reported that about 320 million people in India are
working in unorganized sector and around 300 million
people are unemployed [36]. According to Horton and
Das World Bank definition of poverty (an income of less
than USD $1.25 a day) is more sensitive, embracing 42%
of India’s people [37]. Medicines for chronic diseases are
often unaffordable as they require lifelong treatment
with multiple medications [38]. Further, the need for
other mandatory expenditure like food, housing, and
other family members living on the salary will change
the affordability estimate. Affordability can be severely
affected by multiple illnesses in the family or if the earn-
ing member is one to fall ill. Therefore, the information
on affordability is to be interpreted with caution and
should not impact on the potential for taking policy de-
cisions for medicine prices in India.
Policy options to improve access to affordable medicines
Awareness programmes targeting various stakeholders
like doctors, patients, consumer groups, and the media
are needed. From the various policies suggested [31,39,40]
for cost containment and promotion of generics that
can be implemented in Indian context for promotion of
awareness are: involvement of reputed organizations
and institutions to participate in the process; involve-
ment of patient associations and consumers group; reliable
quality assurance capacity, including demonstration of
bioequivalence; encouraging generic prescribing (in Indian
context branded-generic prescribing); influencing the
patient to ask for prescription of cheaper version of
medicines. A number of countries have used the results
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inform and guide policies to improve access to medi-
cines [41]. Lebanon is an example where the govern-
ment implemented regressive margins for importers,
wholesalers and retailers; improved transparency by
publishing patient prices on the internet and in the
Lebanon National Drug Index. In another example, the
Government of Tajikistan abolished 20% VAT on medi-
cines. In India we need to have policy actions based on
the evidence generated from medicine price surveys to
improve access to essential medicines.
Therefore, there is need to collect data on the quality
of branded-generics and generics in India which should
be widely disseminated and publicised. Awareness pro-
grams and workshops for medical students and doctors
should be instituted. These workshops should focus on
the disparity in price and availability of different brands
of the same medicine [42]. The central government
may also abolish the 5% VAT, which is borne by
patients. Consumer awareness about medicine prices
will be useful in bringing down the overall prices of
medicines.Conclusion
The present survey provides a clear picture of the poor
availability of essential medicines in public sector facil-
ities in Delhi, which are the primary source of medicines
for poor populations. Therefore, low-income patients are
forced to buy medicines from private sector or forego
treatment since affordability is a major issue for a large
proportion of the Indian population. Findings have given
insight to policymakers about the significance of EML
for different healthcare levels, magnitude of pooled pro-
curement, importance of regular supply and quantifica-
tion of medicines for the public sector and significance
of prescribing low priced generic version (branded-gen-
eric) of medicines in the private sector. The various
policy options suggested including the continuous mo-
nitoring and evaluation of the system will be helpful in
making the government policy of providing ‘free-medi-
cines-to-all’ a reality. Policymakers have a good oppor-
tunity to improve the situation by better spending on
medicines and more spending on health.
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